dc.contributor.author |
Nock, B |
en |
dc.contributor.author |
Nikolopoulou, A |
en |
dc.contributor.author |
Chiotellis, E |
en |
dc.contributor.author |
Loudos, G |
en |
dc.contributor.author |
Maintas, D |
en |
dc.contributor.author |
Reubi, JC |
en |
dc.contributor.author |
Maina, T |
en |
dc.date.accessioned |
2014-03-01T01:18:29Z |
|
dc.date.available |
2014-03-01T01:18:29Z |
|
dc.date.issued |
2003 |
en |
dc.identifier.issn |
1619-7070 |
en |
dc.identifier.uri |
https://dspace.lib.ntua.gr/xmlui/handle/123456789/15041 |
|
dc.subject |
99mTc |
en |
dc.subject |
Bombesin |
en |
dc.subject |
Gastrin releasing peptide |
en |
dc.subject |
Tetraamine chelator |
en |
dc.subject |
Tumour imaging |
en |
dc.subject.classification |
Radiology, Nuclear Medicine & Medical Imaging |
en |
dc.subject.other |
bombesin derivative |
en |
dc.subject.other |
demobensin 1 technetium tc 99m |
en |
dc.subject.other |
G protein coupled receptor |
en |
dc.subject.other |
gastrin releasing peptide receptor |
en |
dc.subject.other |
unclassified drug |
en |
dc.subject.other |
bombesin |
en |
dc.subject.other |
diagnostic agent |
en |
dc.subject.other |
drug derivative |
en |
dc.subject.other |
gastrin releasing peptide |
en |
dc.subject.other |
radiopharmaceutical agent |
en |
dc.subject.other |
technetium 99m demobesin 1 |
en |
dc.subject.other |
technetium complex |
en |
dc.subject.other |
animal experiment |
en |
dc.subject.other |
animal model |
en |
dc.subject.other |
article |
en |
dc.subject.other |
binding affinity |
en |
dc.subject.other |
cancer cell culture |
en |
dc.subject.other |
controlled study |
en |
dc.subject.other |
drug accumulation |
en |
dc.subject.other |
drug clearance |
en |
dc.subject.other |
drug degradation |
en |
dc.subject.other |
drug distribution |
en |
dc.subject.other |
drug potency |
en |
dc.subject.other |
drug receptor binding |
en |
dc.subject.other |
drug stability |
en |
dc.subject.other |
drug tissue level |
en |
dc.subject.other |
drug uptake |
en |
dc.subject.other |
human |
en |
dc.subject.other |
human cell |
en |
dc.subject.other |
injection |
en |
dc.subject.other |
kidney metabolism |
en |
dc.subject.other |
liver homogenate |
en |
dc.subject.other |
male |
en |
dc.subject.other |
mouse |
en |
dc.subject.other |
nonhuman |
en |
dc.subject.other |
prostate adenocarcinoma |
en |
dc.subject.other |
target organ |
en |
dc.subject.other |
tumor scintiscanning |
en |
dc.subject.other |
tumor xenograft |
en |
dc.subject.other |
animal |
en |
dc.subject.other |
antibody specificity |
en |
dc.subject.other |
blood |
en |
dc.subject.other |
cancer transplantation |
en |
dc.subject.other |
cell culture |
en |
dc.subject.other |
cell membrane |
en |
dc.subject.other |
comparative study |
en |
dc.subject.other |
evaluation |
en |
dc.subject.other |
female |
en |
dc.subject.other |
isotope labeling |
en |
dc.subject.other |
kidney |
en |
dc.subject.other |
liver |
en |
dc.subject.other |
metabolic clearance rate |
en |
dc.subject.other |
metabolism |
en |
dc.subject.other |
methodology |
en |
dc.subject.other |
pathology |
en |
dc.subject.other |
prostate tumor |
en |
dc.subject.other |
protein binding |
en |
dc.subject.other |
scintiscanning |
en |
dc.subject.other |
skeletal muscle |
en |
dc.subject.other |
synthesis |
en |
dc.subject.other |
tissue distribution |
en |
dc.subject.other |
Animals |
en |
dc.subject.other |
Bombesin |
en |
dc.subject.other |
Cell Membrane |
en |
dc.subject.other |
Female |
en |
dc.subject.other |
Gastrin-Releasing Peptide |
en |
dc.subject.other |
Humans |
en |
dc.subject.other |
Isotope Labeling |
en |
dc.subject.other |
Kidney |
en |
dc.subject.other |
Liver |
en |
dc.subject.other |
Male |
en |
dc.subject.other |
Metabolic Clearance Rate |
en |
dc.subject.other |
Muscle, Skeletal |
en |
dc.subject.other |
Neoplasm Transplantation |
en |
dc.subject.other |
Organ Specificity |
en |
dc.subject.other |
Organotechnetium Compounds |
en |
dc.subject.other |
Prostatic Neoplasms |
en |
dc.subject.other |
Protein Binding |
en |
dc.subject.other |
Radiopharmaceuticals |
en |
dc.subject.other |
Tissue Distribution |
en |
dc.subject.other |
Tumor Cells, Cultured |
en |
dc.title |
[99mtc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging |
en |
heal.type |
journalArticle |
en |
heal.identifier.primary |
10.1007/s00259-002-1040-x |
en |
heal.identifier.secondary |
http://dx.doi.org/10.1007/s00259-002-1040-x |
en |
heal.language |
English |
en |
heal.publicationDate |
2003 |
en |
heal.abstract |
Demobesin 1 is a potent new GRP-R-selective bombesin (BN) analogue containing an open chain tetraamine chelator for stable technetium-99m binding. Following a convenient labelling protocol, the radiopeptide, [Tc-99m]Demobesin 1, formed in nearly quantitative yields and with high specific activities. Both unlabelled and labelled peptide demonstrated high-affinity binding in membrane preparations of the human androgen-independent prostate adenocarcinoma PC-3 cell line. The IC50 values determined for Demobesin 1 and [Tyro]BN were 0.70+/-0.08 nM and 1.5+/-0.20 nM, respectively, while the K-d defined for [Tc-99m/Tc-99g]Demobesin 1 was 0.67+/-0.10 nM. [Tc-99m]Demobesin 1 was rather stable in murine plasma, whereas it degraded rapidly in kidney and liver homogenates. After injection in healthy Swiss albino mice, [Tc-99m]Demobesin 1 accumulated very efficiently in the target organs (pancreas, intestinal tract) via a GRP-R-mediated process, as shown by in vivo receptor blocking experiments. An equally high and GRP-R-mediated uptake was exhibited by [Tc-99m]Demobesin 1 after injection in PC-3 tumour-bearing athymic mice. The initial high radioligand uptake of 16.2+/-3.1%ID/g in the PC-3 xenografts at 1 h p.i. remained at a similar level (15.61+/-1.19%ID/g) at 4 h p.i. Even after 24 h p.i., when the radioactivity had cleared from all other tissues, a value of 5.24+/-0.67%ID/g was still observed in the tumour. The high and prolonged localization of [Tc-99m]Demobesin 1 at the tumour site and its rapid background clearance are very promising qualities for GRP-R-targeted tumour imaging in man. |
en |
heal.publisher |
SPRINGER-VERLAG |
en |
heal.journalName |
European Journal of Nuclear Medicine and Molecular Imaging |
en |
dc.identifier.doi |
10.1007/s00259-002-1040-x |
en |
dc.identifier.isi |
ISI:000181033800010 |
en |
dc.identifier.volume |
30 |
en |
dc.identifier.issue |
2 |
en |
dc.identifier.spage |
247 |
en |
dc.identifier.epage |
258 |
en |